The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma Research

Background:

• Cytokines and molecularly targeted therapies (VEGF-directed agents, mTOR inhibitors) previously dominated renal cell carcinoma (RCC) treatment.
• Immune checkpoint inhibitors (ICIs) represent a significant advancement, revolutionizing cancer therapy, including for RCC.
• The evolution of RCC treatment reflects a shift from older immunotherapies to novel ICI-based strategies.

Purpose of the Study:

• To review the scientific rationale behind the transition from cytokine-based therapies to ICIs in RCC treatment.
• To summarize pivotal clinical trials evaluating ICIs in various clear cell RCC settings.
• To discuss the increasing complexity of clear cell RCC treatment due to multiple combination therapies.

Main Methods:

• Literature review focusing on fundamental discoveries in cancer immunotherapy.
• Analysis of key clinical trials (CheckMate 025, CheckMate 214, KEYNOTE-426, JAVELIN Renal 101, IMmotion151) for ICIs in clear cell RCC.
• Discussion of current and future treatment paradigms for advanced RCC.

Main Results:

• ICIs have emerged as a cornerstone in RCC treatment, offering new therapeutic options.
• Pivotal trials demonstrate the efficacy of various ICI-based regimens in different treatment settings for clear cell RCC.
• The landscape of RCC treatment is evolving, with numerous combination therapies available and under investigation.

Conclusions:

• The advent of ICIs has fundamentally changed the approach to treating renal cell carcinoma.
• Treatment decisions for clear cell RCC are becoming more complex, requiring consideration of patient-specific factors.
• Future advancements, including biomarker development, are anticipated to further personalize and optimize RCC treatment strategies.